Chimerix Announces Pricing of Public Offering of Common Stock
January 20, 2021 20:03 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock
January 19, 2021 16:19 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious...
Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
January 08, 2021 06:00 ET
|
Chimerix, Inc.
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential...
Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference
January 06, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
December 07, 2020 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
November 05, 2020 16:01 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update
November 05, 2020 07:00 ET
|
Chimerix, Inc.
– Completed Rolling NDA Submissions for Both BCV Tablet and Suspension Formulations as Medical Countermeasure for Smallpox – – First Patient Visit for DSTAT Phase 3 AML Study Expected in Early...
Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
October 29, 2020 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Participate in Upcoming Investor Conferences
September 10, 2020 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Second Quarter 2020 Financial Results and Provides Operational Update
August 10, 2020 07:00 ET
|
Chimerix, Inc.
– Completion of BCV NDA Rolling Submission Planned for Third Quarter 2020 – – Currently Enrolling Phase 2/3 Study of DSTAT in Patients with COVID-19; Phase 2 Enrollment Completion Expected in Fourth...